Fennec Pharmaceuticals Inc (NASDAQ:FENC - Get Free Report) CEO Rosty Raykov sold 44,300 shares of the business's stock in a transaction on Friday, April 5th. The stock was sold at an average price of $10.75, for a total transaction of $476,225.00. Following the completion of the sale, the chief executive officer now owns 187,471 shares in the company, valued at approximately $2,015,313.25. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.
Rosty Raykov also recently made the following trade(s):
- On Wednesday, April 3rd, Rosty Raykov sold 40,584 shares of Fennec Pharmaceuticals stock. The stock was sold at an average price of $10.78, for a total transaction of $437,495.52.
Fennec Pharmaceuticals Stock Down 2.0 %
NASDAQ:FENC traded down $0.22 during mid-day trading on Friday, hitting $10.69. 103,807 shares of the stock traded hands, compared to its average volume of 109,738. The stock has a market capitalization of $289.06 million, a price-to-earnings ratio of -17.52 and a beta of 0.38. Fennec Pharmaceuticals Inc has a 52 week low of $6.30 and a 52 week high of $11.92. The firm's 50 day moving average is $10.01 and its two-hundred day moving average is $9.14.
Analyst Upgrades and Downgrades
A number of analysts have recently weighed in on FENC shares. HC Wainwright boosted their target price on shares of Fennec Pharmaceuticals from $17.00 to $18.00 and gave the stock a "buy" rating in a report on Thursday. Wedbush restated an "outperform" rating and issued a $16.00 target price on shares of Fennec Pharmaceuticals in a report on Monday, March 18th. Finally, Craig Hallum boosted their target price on shares of Fennec Pharmaceuticals from $17.00 to $18.00 and gave the stock a "buy" rating in a report on Monday, March 18th.
Check Out Our Latest Stock Analysis on Fennec Pharmaceuticals
Hedge Funds Weigh In On Fennec Pharmaceuticals
Several hedge funds have recently added to or reduced their stakes in the company. Sonic GP LLC bought a new position in Fennec Pharmaceuticals during the 4th quarter valued at about $23,111,000. Vanguard Group Inc. grew its holdings in Fennec Pharmaceuticals by 1,294.3% during the 4th quarter. Vanguard Group Inc. now owns 1,140,063 shares of the company's stock valued at $12,792,000 after purchasing an additional 1,058,295 shares during the last quarter. BlackRock Inc. grew its holdings in Fennec Pharmaceuticals by 1,507.6% during the 2nd quarter. BlackRock Inc. now owns 830,119 shares of the company's stock valued at $7,330,000 after purchasing an additional 778,481 shares during the last quarter. AIGH Capital Management LLC boosted its position in Fennec Pharmaceuticals by 6.9% in the 3rd quarter. AIGH Capital Management LLC now owns 373,526 shares of the company's stock valued at $2,805,000 after buying an additional 24,069 shares during the period. Finally, Gendell Jeffrey L boosted its position in Fennec Pharmaceuticals by 0.9% in the 3rd quarter. Gendell Jeffrey L now owns 285,992 shares of the company's stock valued at $2,148,000 after buying an additional 2,579 shares during the period. 55.51% of the stock is currently owned by institutional investors.
Fennec Pharmaceuticals Company Profile
(
Get Free Report)
Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children.
Recommended Stories
Before you consider Fennec Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Fennec Pharmaceuticals wasn't on the list.
While Fennec Pharmaceuticals currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
